<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105999">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02047162</url>
  </required_header>
  <id_info>
    <org_study_id>6469</org_study_id>
    <nct_id>NCT02047162</nct_id>
  </id_info>
  <brief_title>Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients--Pakistan</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Trial of the Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients in Pakistan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Oriented Preventive Education</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn whether bismuth subsalicylate can reduce use of
      antibiotics among adults with diarrhea in Pakistan.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>use of antimicrobial medications</measure>
    <time_frame>within 5 days of enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's perceived need for antibiotics</measure>
    <time_frame>Within 48 h of enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>additional care obtained for diarrhea</measure>
    <time_frame>within 48 h of enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Use of antidiarrheal medications, visits to other health professionals for diarrhea or complications of diarrhea, or expenditures on consultations and treatments for diarrheal illness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional care obtained for diarrheal illness</measure>
    <time_frame>within 5 days of enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Use of antidiarrheal medications, visits to other health professionals for diarrhea or complications of diarrhea, or expenditures on consultations and treatments for diarrheal illness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease severity and duration</measure>
    <time_frame>within 5 days of enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to first formed stool Number of stools during first 48 h of observation Duration of abdominal pain Duration of nausea Time to resolution of illness (any of the following symptoms: diarrhea, nausea, vomiting, abdominal pain) Severity of all symptoms of illness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient experience with the study drug</measure>
    <time_frame>within 5 days of enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>i.	Satisfaction with resolution of symptoms ii.	Satisfaction with esthetics of study medication iii.	Adverse effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Bismuth subsalicylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bismuth subsalicylate, 262 mg/chewable tablet, 2 tablets every hour as needed up to 16 tablets per 24 hours, for up to 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo chewable tablets, 2 every hour as needed up to 16 tablets per 24 h, for up to 48 h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth subsalicylate</intervention_name>
    <arm_group_label>Bismuth subsalicylate</arm_group_label>
    <other_name>Pepto-Bismol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Chewable tablets identical to intervention tablets, but missing the bismuth subsalicylate</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persons aged 15 - 65 years old

          -  Presenting with mild to moderate, non-bloody, acute diarrhea (â‰¥3 loose stools/day for
             &lt;3 days) to participating health care settings

          -  For whom the study physicians recommend antimicrobial treatment

        Exclusion Criteria:

          -  Is pregnant

          -  Requires hospitalization

          -  Has signs or symptoms of septicemia

          -  Has a primary complaint of another acute illness

          -  Has a serious chronic illness

          -  Has an allergy to aspirin

          -  Has been exposed to antimicrobial or antidiarrheal medications within 72 hours of
             enrollment

          -  Previously enrolled in study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Bowen, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mubina Agboatwalla, MD</last_name>
    <phone>923 332 13 1960</phone>
    <email>agboat@hope-ngo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HOPE</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agboatwalla</last_name>
      <email>agboat@hope-ngo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>January 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centers for Disease Control and Prevention</investigator_affiliation>
    <investigator_full_name>Anna Bowen</investigator_full_name>
    <investigator_title>Medical Epidemiologist</investigator_title>
  </responsible_party>
  <keyword>diarrhea</keyword>
  <keyword>gastroenteritis</keyword>
  <keyword>antimicrobial drug resistance</keyword>
  <keyword>antimicrobial agents</keyword>
  <keyword>Pakistan</keyword>
  <keyword>ambulatory care</keyword>
  <keyword>bismuth</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Bismuth</mesh_term>
    <mesh_term>Bismuth subsalicylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
